MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:11Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

← Older revision		Revision as of 03:16, 19 May 2026
Line 27:		Line 27:
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring = Blood pressure with concurrent antihypertensives or alpha-blockers.		\| monitoring = Blood pressure with concurrent antihypertensives or alpha-blockers.
	\| counseling = '''Contraindicated with any nitrate''' — life-threatening hypotension. Caution with alpha-blockers — separate doses by ≥4 h. The "blue tint" visual side effect comes from PDE6 cross-reactivity in retinal cones.		\| counseling = '''Contraindicated with any nitrate''', life-threatening hypotension. Caution with alpha-blockers, separate doses by ≥4 h. The "blue tint" visual side effect comes from PDE6 cross-reactivity in retinal cones.
	\| anecdotes =		\| anecdotes =
	\| seealso = [[Avanafil]], [[Tadalafil]], [[Vardenafil]]		\| seealso = [[Avanafil]], [[Tadalafil]], [[Vardenafil]]

MDElliottMD: Create Sildenafil scaffold

2026-05-15T15:30:23Z

Create Sildenafil scaffold

New page

{{MedTemplate
| generic = Sildenafil
| brand = Viagra, Revatio
| classes = PDE5 Inhibitor
| uses = <vote slug="erectile-dysfunction-use">Erectile dysfunction</vote>, <vote slug="pulmonary-hypertension-use">Pulmonary arterial hypertension</vote>
| starting_dose = 50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH)
| preparations = 25, 50, 100 mg tabs (Viagra); 20 mg tabs and 10 mg/mL oral suspension (Revatio)
| fda_max = 100 mg/d (ED); 20 mg TID (PAH)
| routes = Oral, IV (Revatio)
| onset = 30–60 min
| duration = ~4 h
| halflife = ~4 h
| bioavailability = ~40%
| pregnancy = Category B
| legal = Rx-only in US
| mechanism = Selective inhibitor of phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in vascular smooth muscle. In the corpus cavernosum, potentiates the NO/cGMP cascade triggered by sexual stimulation.
| intro = Sildenafil was the first PDE5 inhibitor (FDA-approved 1998) and remains the prototype. Originally developed for angina; repurposed after a famous trial-side-effect observation. Same molecule is marketed as Revatio for pulmonary arterial hypertension at lower individual doses but higher daily totals.
| indications =
| dosing =
| effects =
| pk_absorption = ~40%; reduced by high-fat meals.
| pk_distribution = Plasma protein binding ~96%.
| pk_metabolism = Hepatic via CYP3A4 (primary), CYP2C9.
| pk_elimination = Mainly fecal as metabolites.
| pharmacodynamics =
| interactions = <pharmaInteractions/>
| pregnancy_details =
| monitoring = Blood pressure with concurrent antihypertensives or alpha-blockers.
| counseling = '''Contraindicated with any nitrate''' — life-threatening hypotension. Caution with alpha-blockers — separate doses by ≥4 h. The "blue tint" visual side effect comes from PDE6 cross-reactivity in retinal cones.
| anecdotes =
| seealso = [[Avanafil]], [[Tadalafil]], [[Vardenafil]]
| references = <references/>
}}

[[Category:PDE5 Inhibitors]]
[[Category:Medicines]]

Sildenafil - Revision history

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

MDElliottMD: Create Sildenafil scaffold